Calamos Advisors LLC Raises Stock Position in Harrow, Inc. (NASDAQ:HROW)

Calamos Advisors LLC lifted its position in shares of Harrow, Inc. (NASDAQ:HROW) by 35.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 11,913 shares of the company’s stock after buying an additional 3,103 shares during the period. Calamos Advisors LLC’s holdings in Harrow were worth $400,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. First Turn Management LLC purchased a new position in Harrow during the 3rd quarter valued at about $14,683,000. JPMorgan Chase & Co. increased its stake in shares of Harrow by 443.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock worth $10,717,000 after purchasing an additional 194,480 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Harrow during the 3rd quarter worth approximately $8,572,000. Charles Schwab Investment Management Inc. increased its position in Harrow by 195.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock worth $11,313,000 after buying an additional 166,602 shares in the last quarter. Finally, Braidwell LP increased its position in Harrow by 47.9% during the third quarter. Braidwell LP now owns 439,638 shares of the company’s stock worth $19,766,000 after buying an additional 142,450 shares in the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Stock Up 0.2 %

HROW stock opened at $30.89 on Thursday. The stock has a market capitalization of $1.10 billion, a P/E ratio of -32.86 and a beta of 0.69. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. Harrow, Inc. has a one year low of $9.26 and a one year high of $59.23. The company has a 50 day moving average price of $35.22 and a two-hundred day moving average price of $39.64.

Wall Street Analysts Forecast Growth

Separately, B. Riley dropped their price objective on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research report on Wednesday, December 4th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.